These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36960527)

  • 1. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
    Zhang C; Zhang J; Cheng YJ
    Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis.
    Wang H; Kong QZ; Li YY; Yang XY; Zuo XL
    J Dig Dis; 2024 Mar; 25(3):163-175. PubMed ID: 38577962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis.
    Yang X; Wang JX; Han SX; Gao CP
    Medicine (Baltimore); 2019 Feb; 98(7):e14396. PubMed ID: 30762742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose dual therapy
    Zhou BG; Mei YZ; Zhang M; Jiang X; Li YY; Ding YB
    Therap Adv Gastroenterol; 2023; 16():17562848221147756. PubMed ID: 36644129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG; Jiang X; Ding YB; She Q; Li YY
    Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
    Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
    Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy
    Mei H; Guo Y; Zhao JT; Yang J; Sun WJ; Zhang DK; He P; Shi G; Su NY; Han R; Lan CH
    Therap Adv Gastroenterol; 2022; 15():17562848221142925. PubMed ID: 36600686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis.
    Xu H; Wang W; Ma X; Feng R; Su Y; Cheng L; Yang Y; Zhang D
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):775-786. PubMed ID: 32639419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis.
    Guo B; Cao NW; Zhou HY; Chu XJ; Li BZ
    Microb Pathog; 2021 Mar; 152():104661. PubMed ID: 33249167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Chen J; Zhang Y; Min H; Zhi J; Ma S; Dong H; Yan J; Chi X; Zhang X; Yang Y
    Helicobacter; 2024; 29(2):e13077. PubMed ID: 38682268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China: A Systemic Review and Network Meta-Analysis.
    Li J; Shi H; Zhou F; Xie L; Lin R
    J Clin Gastroenterol; 2024 Jan; 58(1):12-23. PubMed ID: 38084866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
    Kim JS; Ko W; Chung JW; Kim TH
    Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line and rescue therapy for refractory
    de Moraes Andrade PV; Monteiro YM; Chehter EZ
    World J Gastroenterol; 2023 Jan; 29(2):390-409. PubMed ID: 36687120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
    Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
    Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Macedo Silva V; Lima Capela T; Freitas M; Boal Carvalho P; Magalhães J; Cotter J
    Helicobacter; 2023 Jun; 28(3):e12962. PubMed ID: 36828647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.